Mark Nance, chief legal officer and general counsel of the troubled drug company Insys Therapeutics Inc., plans to resign from the company July 31, apparently giving up a $613,000 retention bonus.

Nance, who could not be reached for comment Tuesday, joined the company last October as a member of its senior management team. At the time the Phoenix-based pharma company was facing criminal and False Claims Act allegations that it bribed doctors to prescribe one of its popular opioid drugs, Subsys.

His hiring was part of a major management shakeup at the company that also included a new CEO and chief financial officer. Three months ago the company agreed to pay hefty retention bonuses to the three executives if they remained on the job for one more year, until April 2020.

“The retention bonuses include certain terms and conditions, including full clawback if any such officer's employment terminates under certain conditions within twelve months of the agreement date,” according to the company's 8-K filing with the U.S. Securities and Exchange Commission. It did not say what the “certain conditions” were, and the company did not immediately return messages Tuesday.

Following the bonuses, the company reached a $225 million global settlement with the U.S. Department of Justice on June 5. Insys also signed a five-year corporate integrity agreement with the U.S. Department of Health and Human Services.

Attorney Geoffrey Hobart from the Washington office of Covington & Burling represented the company on both agreements. Hobart was traveling Tuesday and could not be reached for comment.

Then, on June 10, Insys filed for Chapter 11 bankruptcy protection in U.S. Bankruptcy Court in Delaware. In a recent SEC filing the company said it had a cash balance as of June 10 of $37.4 million.

The filing said Insys also has about $4.6 million held in retainers for services, including nearly $3.5 million with Weil, Gotshal & Manges.

Nance came to Insys after serving as senior vice president and global general counsel at pharmaceutical giant Mylan N.V. Prior to joining Mylan in early 2012, he was general counsel at General Electric Co.'s pharmaceutical and life sciences businesses.

Nance also served in the office of policy planning of the U.S. Federal Trade Commission, focusing on areas of technology and antitrust policy and for seven years as a founding member of the U.S. National Science Advisory Board for Biosecurity.

At Insys Nance succeeded general counsel Franc Del Fosse, who was moved to the newly created position of senior vice president of corporate affairs and left the company a few months later.

Meanwhile eight other former executives, including founder and chairman of the board John Kapoor, have been convicted in the bribery scheme.

Earlier this month the Arizona attorney general's office filed suit against Kapoor and two other former executives for allegedly engaging in a marketing scheme to increase sales of Subsys.